TC221

TC221 is an investigational **boron-containing small molecule** being developed by **TAE Life Sciences** as a boron delivery agent for **Boron Neutron Capture Therapy** in oncology. The compound is designed to selectively accumulate **boron-10** in tumor cells; after neutron irradiation, the boron undergoes a nuclear reaction that produces short-range high linear energy transfer particles, including alpha particles, intended to kill malignant cells while limiting damage to adjacent normal tissue. Preclinical descriptions indicate that TC221 has targeting properties similar to boronophenylalanine but with improved solubility and superior tumor boron delivery, and it has been discussed for cancers including **lung cancer, colon cancer, and skin cancer**.